


Improving patient outcomes in advanced NSCLC: a focus on molecular diagnostics and resistance

SAVE THE DATE

April 13, 2018, 18:40–19:40

Room C, Palexpo, Geneva, Switzerland



OBJECTIVES

Overview the roles of immunotherapy and targeted therapy in treating patients with advanced NSCLC

Highlight the prognostic implications following identification of oncogenic driver aberrations

Discuss the advantages and practicalities of next-generation sequencing (NGS) versus sequential testing (eg by IHC and FISH) to optimize molecular diagnostics

Overview mechanisms of resistance to immunotherapy and targeted therapy and the requirements for routine testing

AGENDA

18:40–18:45	WELCOME AND INTRODUCTIONS Luis Paz-Ares (Chair)
18:45–19:05	AN INTRODUCTION TO TARGETED AND IMMUNE THERAPIES Including opportunity for Q&A Raffaele Califano
19:05–19:25	OPTIMIZING DIAGNOSTICS FOR MOLECULAR ABERRATIONS Including opportunity for Q&A Luis Paz-Ares
19:25–19:40	UNDERSTANDING AND MANAGING RESISTANCE Including opportunity for Q&A Enriqueta Felip
19:40	CLOSE Luis Paz-Ares (Chair)